Amwell makes grant to new employee under inducement plan
Rhea-AI Summary
Amwell (NYSE: AMWL) announced on February 18, 2026 a grant of 61,559 RSUs to one new employee as a material inducement to employment. The grant was approved by the Compensation Committee under Amwell’s Inducement Plan and relies on the NYSE employment inducement exemption.
The RSUs vest 25% on the first anniversary of the grant, with the remaining 75% vesting in equal pro rata increments every three months thereafter over three years (beginning the first calendar day of the month after the three-month period following the Initial Vesting Date).
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows 1 peer (LFMD) up 3.39%. Sector peers were mixed, with some names like HCAT and SOPH up and others like FORA and MNDR down.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings results | Neutral | +0.2% | Reported Q4 and full-year 2025 financial results with earnings call webcast. |
| Feb 05 | Earnings date | Neutral | +4.5% | Announced timing of Q4 and full-year 2025 results and investor call. |
| Nov 04 | Earnings results | Neutral | -0.8% | Released Q3 2025 financial results and scheduled related conference call. |
| Oct 27 | Earnings & conferences | Neutral | -3.3% | Outlined Q3 2025 earnings date and participation in upcoming investor conferences. |
Recent disclosures have focused on earnings and investor updates, with generally modest single-day price reactions around these events.
Over the last several months, Amwell has emphasized financial reporting and investor communication. It reported third quarter 2025 results on Nov. 4, 2025 and followed with notifications and results for fourth quarter and full year 2025 around Feb. 12, 2026. These earnings and scheduling releases were accompanied by conference calls and webcasts but only small one-day price moves. Against that backdrop, the new RSU inducement grant represents a routine compensation-related item rather than a major strategic shift.
Market Pulse Summary
This announcement details a standard equity compensation action: a 61,559-share RSU grant to a new employee as a material inducement to join Amwell. The award vests 25% after one year and the remaining 75% quarterly over three years, contingent on continued employment, and was approved under the company’s inducement plan consistent with NYSE Rule 303A.08. In the context of recent earnings and regulatory filings, this appears as routine governance rather than a transformative corporate event.
Key Terms
rsus financial
class a common stock financial
inducement plan financial
employment inducement exemption regulatory
AI-generated analysis. Not financial advice.
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, announced that on February 18, Amwell made a grant of RSUs of 61,559 shares of its Class A common stock to one new employee. The grant was offered as material inducement to the employee’s employment with Amwell. The RSUs will vest as follows, subject to the employee’s continued employment through the applicable vesting date:
The grant described in this press release was approved by the Compensation Committee of the Amwell’s Board of Directors pursuant to the Amwell’s Inducement Plan and made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. Amwell is issuing this press release pursuant to Rule 303A.08.
About Amwell
Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn.
Media:
Press@amwell.com
Investor:
Asher Dewhurst
amwell@icrhealthcare.com
Notice of Ownership
All materials contained herein are the property of American Well Corporation and are copyrighted under United States law and applicable international copyright laws and treaty provisions. The materials contained herein are not work product or "work for hire" on behalf of any third party. The materials contained herein constitute the confidential information of American Well Corporation, except for specific data elements provided by third parties, which are the confidential information of such third parties. The content contained herein results from the application of American Well proprietary processes, analytical frameworks, algorithms, business methods, solution construction aids and templates, all of which are and remain the property of American Well Corporation.
Trademark Notice
All of the trademarks, service marks and logos displayed on these materials (the "Trademark(s)") are registered and unregistered trademarks of American Well Corporation or third parties who have licensed their Trademarks to American Well Corporation. Except as expressly stated in these terms and conditions, you may not reproduce, display or otherwise use any Trademark without first obtaining American Well Corporation's written permission.